tak-994 tak-994 tak-994 is an orexin receptor agonist which is under development by takeda for the treatment of narcolepsy. it is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (ox2) (>700-fold selectivity over the orexin receptor 1 (ox1)). tak-994 is related to danavorexton (tak-925). the compound reached phase 2 clinical trials for narcolepsy. however, clinical development was discontinued in october 2021 for safety reasons. the chemical structure of tak-994 has yet to be disclosed. tak-994clinical dataroutes ofadministrationoraldrug classorexin receptor agonist